Want to see LH full AI Analyst Report?
Labcorp Holdings (LH) Price & Analysis
LH Stock Chart & Stats
- Day’s Range
- $358.73 - $370.97
- 52-Week Range
- $244.52 - $371.00
- Previous Close
- $368.16
- Volume
- 649.63K
- Average Volume (3M)
- 764.20K
- Market Cap
- $29.31B
- Enterprise Value
- $31.67B
- Total Cash (Recent Filing)
- $261.80M
- Total Debt (Recent Filing)
- $6.78B
- Price to Earnings (P/E)
- 29.5
- Beta
- 0.33
- Next Earnings
- Feb 11, 2027
- EPS Estimate
- 4.51
- Next Dividend Ex-Date
- Nov 24, 2026
- Dividend Yield
- 0.80%
Bulls Say, Bears Say
Bulls Say
Broad-based Growth And Margin Expansion
Growth is broad enough to support durable operating improvement rather than relying on a single product or customer. Revenue expansion combined with higher margins indicates operating leverage and productivity benefits, strengthening the company’s ability to grow earnings and cash flow over the next several quarters.
Biopharma Laboratory Backlog
The large BLS backlog provides meaningful visibility into future revenue conversion and supports the durability of the drug-development services franchise. Strong book-to-bill and double-digit organic growth also indicate sustained demand from biopharma customers, while expanded laboratory capacity can support continued execution.
Specialty Diagnostics And Innovation
Faster specialty-testing growth can improve Labcorp’s mix and deepen physician relationships because specialty orders often generate additional core laboratory testing. FDA-cleared and approved offerings in oncology, neurology, and precision medicine broaden the company’s differentiated platform and support longer-term relevance.
Bears Say
PAMA Reimbursement Pressure
The proposed reimbursement reductions represent a structural pressure on the diagnostics business rather than a temporary fluctuation. Lower Medicare and Medicaid rates could compress revenue and margins across multiple years, requiring productivity savings, growth, and mix improvement to preserve the company’s earnings trajectory.
Meaningful Leverage
Although leverage has improved from 2024–2025, the debt load remains a meaningful fixed obligation relative to equity. This reduces balance-sheet flexibility and makes sustained earnings and cash generation important for continued deleveraging, acquisitions, capital returns, and resilience if operating conditions weaken.
Moderate Cash Conversion And Below-peak Margins
Labcorp generates substantial absolute cash, but cash conversion is not fully keeping pace with reported earnings, limiting internal funding efficiency. Profitability has recovered from 2023 yet remains below prior peaks, so additional execution is needed before the business can demonstrate fully restored margin durability.
Labcorp Holdings News
LH FAQ
What was Labcorp Holdings’s price range in the past 12 months?
What is Labcorp Holdings’s market cap?
When is Labcorp Holdings’s upcoming earnings report date?
How were Labcorp Holdings’s earnings last quarter?
Is Labcorp Holdings overvalued?
Does Labcorp Holdings pay dividends?
What is Labcorp Holdings’s EPS estimate?
How many shares outstanding does Labcorp Holdings have?
What happened to Labcorp Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Labcorp Holdings?
What is the TipRanks Smart Score and how is it calculated?
Labcorp Holdings Stock Smart Score
Company Description
Labcorp Holdings
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter
- Employees
- 71,000
- Website
- www.labcorp.com
- Address
- 358 South Main Street, Burlington, NC, 27215, US
Labcorp Holdings (LH) Earnings & Revenues
LH Company Deck
LH Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. LabCorp reported broad-based revenue growth, margin expansion, 14.5% adjusted EPS growth, higher 2026 guidance, strong diagnostics and biopharma laboratory demand, a robust backlog, and multiple specialty testing and acquisition opportunities. The principal negative issue was the proposed PAMA reimbursement reduction and its estimated $125 million 2027 impact, along with smaller ACA and foreign exchange headwinds. Management emphasized multiple stated offsets, including organic growth, BLS momentum, Launchpad savings, and business development, so the highlights significantly outweighed the lowlights.
View all LH earnings summariesLH Net sales Breakdown
- 77.96% Dx
- 22.21% BLS
- -0.16% Intercompany eliminations
LH Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 6 |
| Technical Analysis | 2 | 2 | 6 |
| Moving Averages | 12 | 0 | 0 |










